This "Boring" Dividend King Is Quietly Turning Into a Growth Machine -- and Many Investors Are Missing It
2026-07-24 14:15
•James Brumley •The Motley Fool
•••••• •• Axe Capital view
Not-So-Boring Growth: What J&J’s Shift Means for Investors
Johnson & Johnson’s cancer drug business is accelerating, challenging its image as just a dividend-stock stalwart.
Johnson & Johnson is shedding its slow-growth, dividend-paying reputation by leaning heavily into oncology, with drugs like Darzalex growing nearly 19% a year. This isn’t just puffery—cancer treatments globally are expected to grow at over 11% annually, and J&J aims for $50 billion in sales by 2030. For South African investors, the direct play on J&J is limited, but the broader message is worth noting: sectors traditionally seen as stable income streams can pivot to real growth given the right tailwinds. In the local context, this mirrors what we might look for in companies like Sanlam or Nedbank, where shifts in underlying businesses or market drivers can similarly disrupt slow growth narratives. The USD/ZAR rate may also react attractively to global pharma optimism, given rand sensitivity to tech and healthcare flows. Still, J&J’s transition hinges on regulatory wins and competitive pressures, so investors must watch carefully for setbacks. this is just my opinion and not financial advice
I’d watch J&J selectively via global funds if you can access them, but more practically, focus on local banks and insurers that are quietly repositioning for growth rather than pure income. Keep an eye on USD/ZAR for timing exposures.
- JNJ
- USD/ZAR
- Sanlam
- Nedbank
- Regulatory challenges impacting J&J’s oncology pipeline
- Potential rand volatility offsetting global healthcare gains
6/10
Johnson & Johnson is transitioning from a slow-growth dividend stock into a growth machine, driven primarily by its oncology business. The company's cancer drugs, particularly Darzalex, are growing at high-teen rates, positioning J&J to achieve its goal of $50 billion in annual cancer drug sales by 2030. With the global cancer treatment market expected to grow at 11.3% annually through 2035, J&J is well-positioned to capture significant market share despite being primarily viewed as an income investment.
This article was originally published by The Motley Fool and has been adapted here for Axe Capital Trading News.
Publisher: The Motley Fool
Author: James Brumley
Categories: Equities, Earnings, Capital Returns, Healthcare, Consumer, Retail
Tickers: JNJ, KVUE
Sentiment: Positive - The article highlights J&J's accelerating growth in its oncology business with 5.7% operational revenue growth, Darzalex sales growing nearly 19%, and a clear path to achieving $50 billion in cancer drug sales by 2030. The company maintains a strong dividend history (64 consecutive years of increases) while entering a growth phase, supported by a favorable market outlook for cancer treatments growing at 11.3% annually through 2035. Kenvue is mentioned as the consumer-facing spinoff from Johnson & Johnson in 2023, containing brands like Tylenol and Band-Aid. The article notes this spinoff left J&J with a more focused prescription drug and medical device operation, but provides no specific sentiment or performance data about Kenvue itself.
Keywords: Johnson & Johnson, oncology, dividend growth, cancer drugs, Darzalex, pharmaceutical growth, Kenvue spinoff
Insights:
- JNJ: Positive: The article highlights J&J's accelerating growth in its oncology business with 5.7% operational revenue growth, Darzalex sales growing nearly 19%, and a clear path to achieving $50 billion in cancer drug sales by 2030. The company maintains a strong dividend history (64 consecutive years of increases) while entering a growth phase, supported by a favorable market outlook for cancer treatments growing at 11.3% annually through 2035.
- KVUE: Neutral: Kenvue is mentioned as the consumer-facing spinoff from Johnson & Johnson in 2023, containing brands like Tylenol and Band-Aid. The article notes this spinoff left J&J with a more focused prescription drug and medical device operation, but provides no specific sentiment or performance data about Kenvue itself.